Showing results (71-80 of 840) with videos related to
Sort By:
Pageof 84
Hepatology (Baltimore, Md.)|February 14, 2015
Fibrates and cholestasisNisanne S Ghonem, David N Assis, James L BoyerEuropean Journal of Pharmacology|September 2, 2006
Differential effects of hydroxyacetophenone analogues on the transcytotic vesicular pathway in rat liverLukmanee Tradtrantip, James L Boyer, Apichart Suksamrarn, et al.Journal of Lipid Research|June 7, 2012
Evolution of substrate specificity for the bile salt transporter ASBT (SLC10A2)Daniël A Lionarons, James L Boyer, Shi-Ying CaiGut|February 26, 2021
From the origin of NASH to the future of metabolic fatty liver diseaseAndreas Geier, Dina Tiniakos, Helmut Denk, et al.Hepatology (Baltimore, Md.)|June 20, 2019
Liver Injury and Failure in Critical IllnessThomas Horvatits, Andreas Drolz, Michael Trauner, et al.Seminars in Liver Disease|February 13, 2016
Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver DiseaseClaudia D Fuchs, Stefan A Traussnigg, Michael TraunerJournal of Clinical Gastroenterology|March 11, 2005
Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasisMichael Trauner, Martin Wagner, Peter Fickert, et al.Wiener Medizinische Wochenschrift (1946)|November 11, 2008
Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseasesMichael Trauner, Peter Fickert, Emina Halilbasic, et al.Liver International : Official Journal of the International Association for the Study of the Liver|July 30, 2021
Diet and exercise in NAFLD/NASH: Beyond the obviousGeorg Semmler, Christian Datz, Thomas Reiberger, et al.Journal of Hepatology|April 29, 2015
New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyondUlrich Beuers, Michael Trauner, Peter Jansen, et al.Pageof 84